Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This editorial comment reports no new clinical findings, instead discussing a study on the effectiveness of combination therapy with doxazosin and finasteride in patients with benign prostatic hyperplasia.

This research found that the new combination drug Predstanormix Duo, with dutasteride and tamsulosin, is bioequivalent to established treatments for benign prostatic hyperplasia, showing similar pharmacokinetics and safety, potentially improving treatment availability and adherence in high-risk patients.

CTP-543 is generally safe for treating alopecia areata.

In this Phase II study, BAY 43–9006, taken orally for renal cell carcinoma, stabilized disease in 30% of patients, with 40% responding positively, although the targets remain unclear.

This study found that once-daily oxiconazole cream effectively treats tinea infections, achieving at least 80% cure rates, and shows comparable efficacy to other antifungal creams with similar tolerability.

An intact skin barrier is crucial to prevent infection in cases of tether-induced tenosynovitis.

This review highlights how integrating medicinal chemistry with delivery science could transform the limitations of PROTACs—such as poor solubility and low cell permeability—into strengths, potentially advancing these compounds from experimental stages to clinical applications by optimizing their delivery and enhancing therapeutic efficacy.

In this pilot study, Doxil at 60 mg/m² every 4 weeks showed activity against hormone-refractory prostate cancer but was limited by severe mucocutaneous toxicities.

This study reports the first successful use of zanubrutinib to treat a 15-year-old Chinese girl with severe refractory Evans' syndrome, resulting in a sustained recovery of platelet counts and haemoglobin levels.

This article lists the clinically important interactions and skin reactions of several drugs and substances, including THA, FK506, tamoxifen, tamsulosin, tartrazine, tea tree oil, temazepam, and temozolomide, but provides no new clinical results.

This study investigated the modes of action of selected pesticides, suggesting that prochloraz and tebuconazole are linked to reproductive disorders via steroidogenesis disruption, while mancozeb involves inflammatory processes.

This study found that sorafenib was active against desmoid tumors, with 25% of patients achieving a partial response and 70% maintaining stable disease.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

Tigason improved hair growth in a boy with monilethrix without side effects.

This study reported the development of a pH-responsive microreactor that effectively targets infections by eradicating over 99.9% of MRSA and reprogramming the immune response to promote healing, achieving complete infection clearance and tissue regeneration in a 7-day period.

This study demonstrated that 5-azacytidine treatment may reduce TSC lesion-related hair follicles in mice, suggesting chromatin remodeling agents could be effective for tuberous sclerosis cutaneous lesions lacking tuberin.

This study introduced a new spectrofluorometric method using a synthesized organic fluorophore to effectively analyze darolutamide and thalidomide in pharmaceutical preparations and biofluids.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This study reports a successful combination treatment for phospho-organic compound poisoning, using standard therapy with atropine and toxogonin along with exogenous cholinesterases via blood transfusion, showing positive outcomes in patients whose endogenous cholinesterase levels dropped to 20%.

This Patent Highlight discusses recent progress in developing TYK2 inhibitors, which show potential for treating conditions like cancer, alopecia areata, and psoriatic arthritis.

This observational study reviewed thyroid eye disease patients treated with teprotumumab at one center, reporting common side effects like fatigue and dry eye symptoms, with serious adverse events including two cases of blood clots and one pulmonary embolism.

This phase I study determined that a combination of oral SU-014813 and docetaxel is a feasible treatment with a manageable safety profile and potential anti-tumor activity, particularly noted in melanoma and GIST patients.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

This case report describes a successful treatment of alopecia universalis in a 37-year-old female using oral tofacitinib, along with other therapies, resulting in significant hair regrowth without notable safety concerns.

This study found that participants with HR-positive/HER2-negative advanced or metastatic breast cancer treated with sacituzumab govitecan had better quality of life and longer survival compared to standard chemotherapy recipients.

This study reports that once-daily oxiconazole cream effectively achieves mycologic and clinical cures for various fungal infections, with success rates of at least 80% in patients.

This case report describes a patient who experienced rapid hair depigmentation after starting pazopanib for metastatic renal cell carcinoma, which may suggest therapy success despite being distressing.

This study reports that while primary treatment for uveal melanoma has a very high success rate, treating distant metastases, particularly in the liver, remains challenging. Tebentafusp, dependent on HLA-A expression, is the first drug to extend patient survival.

The authors concluded that capecitabine and high-dose toremifene may be an effective treatment option for patients unable to undergo anthracycline or taxane therapies, based on one woman's cancer management.

This synthesis report details the successful development of a C-14 labeled isotopomer of LY300502, a 5α-reductase inhibitor, through a multi-step radiochemical process.